Neal Fowler, Pathalys Pharma CEO
TCGX and JPM help Pathalys raise $105M to go up against Amgen in subset of kidney disease
North Carolina biotech Pathalys Pharma expects to do a rare thing with its nine-figure Series B: file for FDA approval. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
